

Joshua T Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8012525/publications.pdf>

Version: 2024-02-01

150
papers

7,516
citations

76326

40
h-index

56724

83
g-index

154
all docs

154
docs citations

154
times ranked

10407
citing authors

#	ARTICLE	IF	CITATIONS
1	Do Cost-Effectiveness Analyses Account for Drug Genericismation? A Literature Review and Assessment of Implications. <i>Value in Health</i> , 2022, 25, 59-68.	0.3	13
2	Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 235-241.	2.1	1
3	The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. <i>Value in Health</i> , 2022, 25, 1336-1343.	0.3	4
4	Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. <i>Genetics in Medicine</i> , 2022, 24, 1349-1361.	2.4	25
5	Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia. <i>JAMA Network Open</i> , 2022, 5, e2216260.	5.9	27
6	Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. <i>Pharmacoeconomics</i> , 2022, 40, 699-714.	3.3	12
7	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <i>Health Affairs</i> , 2021, 40, 53-61.	5.2	29
8	Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. <i>Acta Diabetologica</i> , 2021, 58, 707-722.	2.5	2
9	Value-based drug pricing in the Biden era: Opportunities and prospects. <i>Health Services Research</i> , 2021, 56, 1093-1099.	2.0	3
10	Dementia Diagnosis Disparities by Race and Ethnicity. <i>Medical Care</i> , 2021, 59, 679-686.	2.4	64
11	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , 2021, 39, 6727-6734.	3.8	5
12	Drug-Pricing Debate Redux – Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. <i>New England Journal of Medicine</i> , 2021, 385, 1923-1924.	27.0	11
13	Measuring –Economic Effects–in Valuing Therapies: An Application to COVID-19 in China. <i>Value in Health</i> , 2020, 23, 1405-1408.	0.3	12
14	Hospital Care at Home: Better, Cheaper, Faster?. <i>Annals of Internal Medicine</i> , 2020, 172, 145.	3.9	5
15	Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. <i>Pharmacoeconomics</i> , 2020, 38, 1135-1145.	3.3	109
16	Preparing the health-care system to pay for new Alzheimer's drugs. <i>Alzheimer's and Dementia</i> , 2020, 16, 1568-1570.	0.8	12
17	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1972.	7.4	20
18	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. <i>Oncologist</i> , 2020, 25, e1117-e1119.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 627-638.	0.9	11
20	Are low and middle-income countries prioritising high-value healthcare interventions?. <i>BMJ Global Health</i> , 2020, 5, e001850.	4.7	13
21	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 96-103.	0.5	26
22	Racial and Ethnic Differences in Knowledge About One's Dementia Status. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1763-1770.	2.6	32
23	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. <i>Journal of General Internal Medicine</i> , 2020, 35, 2629-2636.	2.6	29
24	Dementia diagnosis disparities by race and ethnicity. <i>Alzheimer's and Dementia</i> , 2020, 16, e043183.	0.8	14
25	Optimizing Decision Making in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 265-273.	0.2	1
26	The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20019-e20019.	1.6	1
27	Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12068-12068.	1.6	2
28	Trends of cost-effectiveness studies in sleep medicine. <i>Sleep Medicine</i> , 2019, 53, 176-180.	1.6	11
29	3385 TARGETING DIABETES PREVENTION PROGRAMS: INDIVIDUAL RISK-BASED HEALTH ECONOMIC ANALYSIS. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 155-156.	0.6	0
30	Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. <i>Value in Health</i> , 2019, 22, 1396-1401.	0.3	3
31	Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e948-e956.	2.5	14
32	Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 142.	2.7	5
33	Publication of Decision Model Source Code: Attitudes of Health Economics Authors. <i>Pharmacoeconomics</i> , 2019, 37, 1409-1410.	3.3	9
34	Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1592.	2.6	16
35	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019, 14, e0205633.	2.5	27
36	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. <i>Health Affairs</i> , 2019, 38, 60-67.	5.2	8

#	ARTICLE	IF	CITATIONS
37	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. <i>Value in Health</i> , 2018, 21, 759-761.	0.3	108
38	Patient Variability Seldom Assessed in Cost-effectiveness Studies. <i>Medical Decision Making</i> , 2018, 38, 487-494.	2.4	16
39	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. <i>Value in Health</i> , 2018, 21, 400-406.	0.3	4
40	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018, 182, 212-221.	2.5	17
41	Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , 2018, 59, 1976-1980.	1.3	3
42	QALYs in 2018—Advantages and Concerns. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2473.	7.4	113
43	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 168, 161.	3.9	85
44	A Call for Open-Source Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2018, 168, 529.	3.9	7
45	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 169, 200.	3.9	1
46	Unintended consequences of the potential phase-out of gamma irradiation. <i>F1000Research</i> , 2018, 7, 348.	1.6	10
47	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.	1.1	24
48	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.	1.1	15
49	Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6512-6512.	1.6	0
50	Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18887-e18887.	1.6	0
51	Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. <i>Value in Health</i> , 2017, 20, 193-199.	0.3	18
52	Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. <i>Value in Health</i> , 2017, 20, 200-205.	0.3	39
53	The influence of time horizon on results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 615-623.	1.4	51
54	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , 2017, 37, 790-801.	2.4	9

#	ARTICLE	IF	CITATIONS
55	Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 838-840.	4.4	1
56	Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response. <i>Medical Care</i> , 2017, 55, 912-914.	2.4	12
57	Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1174-1178.	0.8	41
58	ICER's Revised Value Assessment Framework for 2017-2019: A Critique. <i>Pharmacoeconomics</i> , 2017, 35, 977-980.	3.3	13
59	The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 75-83.	2.1	44
60	Economic Evaluation in Adolescent and Young Adult Cancer: Methodological Considerations and the State of the Science. <i>Pediatric Oncology</i> , 2017, , 779-799.	0.5	2
61	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <i>PLoS Medicine</i> , 2017, 14, e1002397.	8.4	68
62	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.9	15
63	Validity and reliability of four value frameworks for cancer drugs.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6603-6603.	1.6	0
64	Network meta-analysis of adjuvant chemotherapy in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12071-e12071.	1.6	0
65	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016, 2016, 1-6.	1.7	3
66	The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. <i>Health Research Policy and Systems</i> , 2016, 14, 86.	2.8	8
67	Q2: National Estimates of Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer's Disease and Related Dementias. <i>Alzheimer's and Dementia</i> , 2016, 12, P253.	0.8	6
68	Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. <i>Pharmacoeconomics</i> , 2016, 34, 1255-1265.	3.3	8
69	Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia. <i>Medical Care</i> , 2016, 54, 380-385.	2.4	13
70	A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. <i>PLoS ONE</i> , 2016, 11, e0168512.	2.5	61
71	Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review. <i>Blood</i> , 2016, 128, 3564-3564.	1.4	0
72	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , 2015, 125, 1866-1869.	1.4	32

#	ARTICLE	IF	CITATIONS
73	Cost Estimation of First-Line Antiretroviral Therapy with Zidovudine/Stavudine as the Nucleoside Backbone in India. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 180-184.	1.5	1
74	Price and value in cancer care. <i>Cancer</i> , 2015, 121, 4097-4098.	4.1	0
75	Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015, 109, 379-385.	1.8	8
76	The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	29
77	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 931-940.	1.4	21
78	Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. <i>Health Affairs</i> , 2015, 34, 253-260.	5.2	28
79	Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. <i>Value in Health</i> , 2015, 18, 308-314.	0.3	32
80	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Resultsâ€™ Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1823-1829.	2.0	30
81	The Changing Face of the Cost-Utility Literature, 1990â€™2012. <i>Value in Health</i> , 2015, 18, 271-277.	0.3	85
82	Vascular Access Choice in Incident Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 183-191.	6.1	110
83	Is the high cost of CML care "worth it"?. <i>Journal of Clinical Oncology</i> , 2015, 33, e17801-e17801.	1.6	1
84	An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , 2015, 126, 2635-2635.	1.4	0
85	Updating Cost-Effectiveness â€™ The Curious Resilience of the \$50,000-per-QALY Threshold. <i>New England Journal of Medicine</i> , 2014, 371, 796-797.	27.0	1,784
86	Unintended Benefits: The Potential Economic Impact Of Addressing Risk Factors To Prevent Alzheimerâ€™s Disease. <i>Health Affairs</i> , 2014, 33, 547-554.	5.2	22
87	FDAâ€™s Proposed Ban on Trans Fats: How Do the Costs and Benefits Stack Up?. <i>Clinical Therapeutics</i> , 2014, 36, 322-327.	2.5	5
88	Evaluation of the Economic Burden of Diseases Associated With Poor Nutrition Status. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 35S-41S.	2.6	16
89	The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 494-508.	1.3	5
90	Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8517-8517.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Pediatric Lipid Screening and Treatment for Cardiovascular Disease Prevention: An Ounce or a Pound?. Current Cardiovascular Risk Reports, 2013, 7, 261-269.	2.0	1
92	Illustrating Potential Efficiency Gains from Using Cost-Effectiveness Evidence to Reallocate Medicare Expenditures. Value in Health, 2013, 16, 629-638.	0.3	19
93	Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. Alzheimer's and Dementia, 2013, 9, 30-38.	0.8	112
94	A Role for Research. American Journal of Preventive Medicine, 2013, 44, S12-S15.	3.0	8
95	Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 513-522.	1.4	13
96	A Systematic Review of the Evidence Concerning the Economic Impact of Employee-Focused Health Promotion and Wellness Programs. Journal of Occupational and Environmental Medicine, 2013, 55, 209-222.	1.7	88
97	Cardiac Screening Prior to Stimulant Treatment of ADHD: A Survey of US-Based Pediatricians. Pediatrics, 2012, 129, 222-230.	2.1	15
98	Rethink chemical risk assessments. Nature, 2012, 489, 27-28.	27.8	23
99	Survey of United States Child and Adolescent Psychiatrists' Cardiac Screening Practices Prior to Starting Patients on Stimulants. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 375-384.	1.3	6
100	Costs and Benefits of Targeted Screening for Causes of Sudden Cardiac Death in Children and Adolescents. Circulation, 2012, 125, 2621-2629.	1.6	55
101	Electrocardiogram Screening for Disorders That Cause Sudden Cardiac Death in Asymptomatic Children: A Meta-analysis. Pediatrics, 2012, 129, e999-e1010.	2.1	73
102	Imputing Productivity Gains From Clinical Trials. Journal of Occupational and Environmental Medicine, 2012, 54, 826-833.	1.7	2
103	Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. Journal of the American College of Cardiology, 2012, 60, 1271-1277.	2.8	126
104	Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. Journal of Vascular Surgery, 2012, 56, 1015-1024.e1.	1.1	83
105	Cost-Effectiveness of Cardiovascular Disease Spending. Journal of the American College of Cardiology, 2012, 60, 2123-2124.	2.8	8
106	A primer on cost-effectiveness analyses for vascular surgeons. Journal of Vascular Surgery, 2012, 55, 1794-1800.	1.1	12
107	Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. Genetics in Medicine, 2012, 14, 663-669.	2.4	56
108	Willingness to pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics (United Kingdom), 2012, 21, 238-251.	1.7	109

#	ARTICLE	IF	CITATIONS
109	A clinical and economic evaluation of enteral nutrition. <i>Current Medical Research and Opinion</i> , 2011, 27, 413-422.	1.9	62
110	Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. <i>Journal of Medical Economics</i> , 2011, 14, 187-193.	2.1	3
111	Screening for Sudden Cardiac Death in the Young. <i>Circulation</i> , 2011, 123, 1911-1918.	1.6	137
112	The Empirical Basis for Determinations of Medical Futility. <i>Journal of General Internal Medicine</i> , 2010, 25, 1083-1089.	2.6	56
113	Letter to the Editor. <i>Risk Analysis</i> , 2010, 30, 1457-1458.	2.7	0
114	What is the value of oncology medicines?. <i>Nature Biotechnology</i> , 2010, 28, 1160-1163.	17.5	16
115	The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses. <i>Medical Decision Making</i> , 2010, 30, 314-319.	2.4	13
116	Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality. <i>Health Affairs</i> , 2010, 29, 1523-1531.	5.2	23
117	Comparative Effectiveness of ST-Segmentâ€“Elevation Myocardial Infarction Regionalization Strategies. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 506-513.	2.2	51
118	Dependence as a unifying construct in defining Alzheimer's disease severity. <i>Alzheimer's and Dementia</i> , 2010, 6, 482-493.	0.8	61
119	Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 595-603.	1.4	12
120	Low-value services in value-based insurance design. <i>American Journal of Managed Care</i> , 2010, 16, 280-6.	1.1	18
121	30 Years of Pharmaceutical Cost-Utility Analyses. <i>Pharmacoeconomics</i> , 2009, 27, 861-872.	3.3	67
122	Decision analytic models for Alzheimer's disease: State of the art and future directions. <i>Alzheimer's and Dementia</i> , 2008, 4, 212-222.	0.8	41
123	Reexamining the Emperorâ€™s New Clothes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 134-137.	2.2	12
124	Using Decision Analysis To Better Evaluate Pediatric Clinical Guidelines. <i>Health Affairs</i> , 2008, 27, 1467-1475.	5.2	11
125	Does Preventive Care Save Money? Health Economics and the Presidential Candidates. <i>New England Journal of Medicine</i> , 2008, 358, 661-663.	27.0	354
126	Reducing Cardiovascular Disease. <i>Diabetes Care</i> , 2008, 31, 1708-1709.	8.6	0

#	ARTICLE	IF	CITATIONS
127	What's More Dangerous, Your Aspirin Or Your Car? Thinking Rationally About Drug Risks (And) Tj ETQq1 1 0.784314 rgBT /Overlock	5.2	20
128	Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2007, 10, 1-269.	6.5	741
129	Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Medical Economic Perspective. American Journal of Kidney Diseases, 2007, 50, 362-365.	1.9	3
130	The Author's Reply. Applied Health Economics and Health Policy, 2006, 5, 270-272.	2.1	0
131	Author's response: Risks and Benefits of Seafood Consumption. American Journal of Preventive Medicine, 2006, 30, 441-443.	3.0	4
132	Comparing Patient Access to Pharmaceuticals in the UK and US. Applied Health Economics and Health Policy, 2006, 5, 177-187.	2.1	36
133	Diesel vs. compressed natural gas for school buses: a cost-effectiveness evaluation of alternative fuels. Energy Policy, 2005, 33, 1709-1722.	8.8	30
134	When Is Evidence Sufficient?. Health Affairs, 2005, 24, 93-101.	5.2	76
135	Health Trade-offs from Policies to Alter Fish Consumption. American Journal of Preventive Medicine, 2005, 29, 324-324.	3.0	16
136	A Quantitative Analysis of Prenatal Methyl Mercury Exposure and Cognitive Development. American Journal of Preventive Medicine, 2005, 29, 353-353.	3.0	119
137	A Quantitative Analysis of Prenatal Intake of n-3 Polyunsaturated Fatty Acids and Cognitive Development. American Journal of Preventive Medicine, 2005, 29, 366-366.	3.0	149
138	A Quantitative Analysis of Fish Consumption and Coronary Heart Disease Mortality. American Journal of Preventive Medicine, 2005, 29, 335-346.	3.0	161
139	A Quantitative Analysis of Fish Consumption and Stroke Risk. American Journal of Preventive Medicine, 2005, 29, 347-352.	3.0	103
140	A Quantitative Risk-Benefit Analysis of Changes in Population Fish Consumption. American Journal of Preventive Medicine, 2005, 29, 325-325.	3.0	197
141	Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A. Human and Ecological Risk Assessment (HERA), 2004, 10, 875-921.	3.4	83
142	A Revised Economic Analysis of Restrictions on the Use of Cell Phones While Driving. Risk Analysis, 2003, 23, 5-17.	2.7	67
143	Fuels for Urban Transit Buses: A Cost-Effectiveness Analysis. Environmental Science & Technology, 2003, 37, 1477-1484.	10.0	37
144	A COMPREHENSIVE EVALUATION OF THE POTENTIAL HEALTH RISKS ASSOCIATED WITH OCCUPATIONAL AND ENVIRONMENTAL EXPOSURE TO STYRENE. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2002, 5, 1-263.	6.5	108

#	ARTICLE	IF	CITATIONS
145	The development of a stochastic physiologically-based pharmacokinetic model for lead. <i>Science of the Total Environment</i> , 2001, 274, 15-19.	8.0	26
146	Title is missing!. <i>Environmental Geochemistry and Health</i> , 1998, 20, 61-66.	3.4	11
147	An Arsenic Exposure Model: Probabilistic Validation Using Empirical Data. <i>Human and Ecological Risk Assessment (HERA)</i> , 1998, 4, 341-377.	3.4	17
148	Life Years Lost at Hazardous Waste Sites: Remediation Worker Fatalities vs. Cancer Deaths to Nearby Residents. <i>Risk Analysis</i> , 1997, 17, 419-425.	2.7	20
149	Noncancer Risk Assessment: A Probabilistic Alternative to Current Practice. <i>Human and Ecological Risk Assessment (HERA)</i> , 1996, 2, 79-102.	3.4	133
150	The use of Monte Carlo simulation techniques to predict population blood lead levels. <i>Environmental Geochemistry and Health</i> , 1994, 16-16, 197-215.	3.4	2